EyePoint, Inc. filed a lawsuit on March 20, 2026, in the Middlesex County Superior Court for the Commonwealth of Massachusetts, accusing Ocular Therapeutix, Inc. of disseminating false or misleading statements regarding EyePoint’s lead experimental eye drug, DURAVYU.
The lawsuit centers on claims that Ocular spread false or misleading information about EyePoint and its drug, potentially harming EyePoint’s reputation and market prospects. Ocular’s lead asset is Axpaxli, a tyrosine kinase inhibitor for wet age‑related macular degeneration (wet AMD), competing with EyePoint’s DURAVYU and established treatments such as Regeneron’s Eylea and Roche’s Vabysmo.
Ocular’s recent positive Phase 3 data for Axpaxli was unexpected and triggered a market reaction, underscoring the high stakes of clinical data in the wet AMD market. The lawsuit adds legal and reputational risk for Ocular, which could influence investor perception and future litigation costs.
Management commentary: Ocular’s executive chairman Pravin U Dugel said, "At Ocular Therapeutix, we have always been courageous, opportunistic, and bold in our efforts to redefine retina. Based on recent developments, we now intend to submit our NDA for AXPAXLI in wet AMD shortly after SOL‑1 year one data, assuming positive results." EyePoint’s CEO Jay Duker had previously questioned Ocular’s management and suggested that negative trial data were being withheld, which may have precipitated the lawsuit.
The lawsuit does not immediately threaten Ocular’s financials, but it introduces legal and reputational risks that could affect investor perception and future litigation costs. The outcome will determine whether Ocular faces potential damages or injunctions related to its marketing claims.
The filing marks a direct legal confrontation between the two companies, highlighting the intense competition in the wet AMD market and the importance of controlling the narrative around clinical data.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.